The Technical Analyst
Marker Therapeutics Inc [MRKR]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Marker Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-3.07% $4.10
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 36.50 mill |
| EPS: | -1.590 |
| P/E: | -2.58 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 8.90 mill |
| Avg Daily Volume: | 0.0200 mill |
| RATING 2024-04-18 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.58 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.44x |
| Company: PE -2.58 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 3.77 - 4.43 ( +/- 8.05%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-06-30 | Lurier Eliot M | Buy | 0 | |
| 2021-03-16 | Eansor Norman David | Buy | 14 285 | Common Stock |
| 2023-06-06 | Eansor Norman David | Buy | 8 000 | Stock Option (right to buy) |
| 2021-03-25 | Eansor Norman David | Buy | 7 142 | Common Stock |
| 2021-03-25 | Eansor Norman David | Sell | 14 285 | Common Stock |
| INSIDER POWER |
|---|
| 100.00 |
| Last 91 transactions |
| Buy: 66 397 235 | Sell: 1 245 536 |
Forecast:
16:00 - $4.10
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $4.10
Forecast 2: 16:00 - $4.10
Forecast 3: 16:00 - $4.10
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $4.10 (-3.07% ) |
| Volume | 0.0130 mill |
| Avg. Vol. | 0.0200 mill |
| % of Avg. Vol | 65.02 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MRKR
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
MRKR
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
Latest Press Releases
2024-04-08 07:00:00 - Press Release
Principal Investigator From City Of Hope National Medical Center Invited To Present Clinical Data From Marker Therapeutics Apollo Study At 11th Global Summit On Hematologic Malignancies
Preliminary data from study in patients with lymphoma enrolled at city of hope national medical center was presented at the 11 th global summit on hematologic malignancies in whistler, bc, canada
2024-03-25 17:45:00 - Press Release
Marker Therapeutics Reports Year-end 2023 Corporate And Financial Results
Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response in first study participant treated with mt-601 (neldaleucel) following car t relapse
2024-03-22 12:30:00 - Press Release
Marker Therapeutics To Present At The H.c. Wainwright 2nd Annual Cell Therapy Virtual Conference
Houston, march 22, 2024 (globe newswire) -- marker therapeutics, inc. (nasdaq: mrkr), a clinical-stage immuno-oncology company focusing on developing next-generation t cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that juan vera, m.d., president and chief executive officer of marker therapeutics, will present at the h.c. wainwright 2nd annual cell therapy virtual conference. this conference will be held virtually on march 26, 2024.
2024-01-22 07:30:00 - Press Release
Marker Therapeutics Receives Approval From United States Adopted Name (usan) Council And International Nonproprietary Names (inn) Expert Committee For “neldaleucel” As Nonproprietary Name For Mt-601
Houston, jan. 22, 2024 (globe newswire) -- marker therapeutics, inc. (nasdaq: mrkr), a clinical-stage immuno-oncology company focusing on developing next-generation t cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, announced today that the united states adopted names (usan) council, and the world health organization (who) international nonproprietary names (inn) expert committee has approved “neldaleucel” as the nonproprietary (generic) name for mt-601, a multi-tumor associated antigen (multitaa)-specific t cell product candidate for the treatment of patients with lymphoma.
2024-01-08 08:24:00 - Press Release
Marker Therapeutics Announces Clinical Program Updates And Pipeline Prioritization
Strategic prioritization of clinical programs with focus on mt-601 in patients with lymphoma multitaa-specific t cell therapies demonstrate clinical safety and positive clinical data across multiple indications marker provides updates supporting the clinical benefits of mt-401 in patients with measurable residual disease (mrd) houston, jan. 08, 2024 (globe newswire) -- marker therapeutics, inc. (nasdaq: mrkr), a clinical-stage immuno-oncology company focusing on developing next-generation t cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced a restructuring of its clinical programs and a strategic prioritization of its multi-tumor associated antigen (multitaa)-specific t cell product pipeline...
Latest News
2024-03-22 12:30:00 - GlobeNewsWire
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
HOUSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics, will present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference. This conference will be held virtually on March 26, 2024.
2023-08-30 08:00:00 - GlobeNewsWire
Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
HOUSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan F. Vera, M.D., President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference, which is being held on September 11-13, 2023 at the Lotte New York Palace Hotel in New York City.
2023-06-01 06:00:00 - PennyStocks
Utilizing Fundamental Analysis for Your Penny Stocks? 3 Tips
Penny stocks, often defined as shares trading for less than $5, present a unique opportunity for investors seeking high potential returns. Despite their low market price, these stocks can offer significant upside potential, particularly when approached with a well-informed strategy.
2023-05-31 11:59:01 - InvestorPlace
Why Is Marker Therapeutics (MRKR) Stock Up 27% Today?
Marker Therapeutics (NASDAQ: MRKR ) stock is rising higher on Wednesday as investors react to positive pre-clinical news from the clinical-stage immuno-oncology company. Today's results come from a test of MT-601 in lymphoma cells.
2023-05-01 12:10:17 - PennyStocks
7 Low Float Penny Stocks To Watch After SNTG Stock Explodes
More low float penny stocks to watch. The post 7 Low Float Penny Stocks To Watch After SNTG Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-11-10 18:48:17 - Zacks Investment Research
MARKER THERAPEUTICS, INC. (MRKR) Reports Q3 Loss, Tops Revenue Estimates
MARKER THERAPEUTICS, INC. (MRKR) delivered earnings and revenue surprises of 38.46% and 393.75%, respectively, for the quarter ended September 2022.
2022-10-14 12:53:33 - PennyStocks
3 Hot Penny Stocks To Buy For Under $1 Right Now
If you're watching the action in the stock market today, you're seeing plenty of chop. The U.S. dollar's strength has pushed broader markets lower, but a mix of positive and negative economic against this week's PPI data and CPI data has brought much more push-pull action.
2022-03-07 16:05:00 - GlobeNewsWire
Marker Therapeutics to Present at Two Upcoming March Investor Conferences
HOUSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Anthony H. Kim, Chief Financial Officer of Marker Therapeutics, will present at two upcoming investor conferences in March.
2022-02-17 13:08:05 - Benzinga
Why Are Marker Therapeutics Shares Trading Lower On Thursday?
Marker Therapeutics Inc (NASDAQ: MRKR) shares are trading lower after Roth Capital downgrades the company from Buy to Neutral and lowers the price target from $3 to $1. The company reported initial results from the Phase 2 trial for MT-401 as a treatment option for Acute myeloid leukemia (AML) in the post-transplant setting.
2022-01-20 07:03:47 - PennyStocks
3 Penny Stocks Under $1 For You List This Week
Penny stocks to watch today The post 3 Penny Stocks Under $1 For You List This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.